Oct 31, 2024 / 07:30AM GMT
Magnus Tolleshaug - Vistin Pharma ASA - Chief Executive Officer
Thank you and hello everyone and welcome to this third quarter, 2024 presentation in Vistin Pharma.
My name is Magnus Tolleshaug CEO of the company and with me, I have Mr. Alexander Karlsen, the CFO of the company, and we will be doing today's presentation.
I will start with the highlights from the third quarter.
The quarter ended at NOK 106 million in the revenue compared to NOK 120 million in the third quarter of 2023. The revenue decrease compared to same quarter last year driven by lower sales volume due to safety stock built and somewhat lower global metformin in prices compared to the third quarter last year.
Year-to-date, we have had the NOK 316 million in revenue compared to NOK 328 million year-to-date last year.
The quarter ended at a record high EBITDA of NOK 29 million versus NOK 27 million in the third quarter last year, the EBITA was positively affected by the product mix, favorable material cost prices and good cost control in the quarter.
The EBITA year-to-date is NOK
Q3 2024 Vistin Pharma ASA Earnings Call Transcript
6 days ago
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers